Joong Hyun Ahn

9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea

Jeongha Mok, Myungsun Lee, Deog Kyeom Kim et al. · The Lancet · 2022 · 61 citations · Full text

Inhibitory effect of receptor for advanced glycation end products (RAGE) on the TGF-β-induced alveolar epithelial to mesenchymal transition

Jeong Sup Song, Chun Mi Kang, Chan Kwon Park et al. · Experimental & Molecular Medicine · 2011 · 41 citations · Full text

Inflammatory Lung Disease, Lung Inflammation, Immunology +20

Treatment Guidelines for Community-acquired Pneumonia in Korea: An Evidence-based Approach to Appropriate Antimicrobial Therapy

Jae‐Hoon Song, Ki-Suck Jung, Moon Won Kang et al. · Infection and Chemotherapy · 2009 · 29 citations · Full text

Community-acquired Pneumonia, Treatment Guidelines, Antibiotics +7

Treatment Guidelines for Community-acquired Pneumonia in Korea: An Evidence-based Approach to Appropriate Antimicrobial Therapy

Jae‐Hoon Song, Moon Won Kang, Do Jin Kim et al. · Tuberculosis & respiratory diseases · 2009 · 29 citations · Full text

Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial

Myungsun Lee, Jeongha Mok, Deog Kyeom Kim et al. · Trials · 2019 · 29 citations · Full text